Cadrenal Therapeutics Inc. Common Stock

CVKD | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.09

$0 (0.00%)

Sep 22, 2026, 2:33 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $3.89M

Enterprise Value $1.5M

Beta 1.84

Average Volume 319.45K

Shares Outstanding (Diluted) 2.91M

Shares Change YoY 48.51%

Institutional Ownership 3.78%

Exchange NASDAQ

ISIN US1276362076

Price Performance

Price Change 1M -35.5%

Price Change 3M -64.4%

Price Change 6M -79.9%

Price Change YTD -85.1%

Price Change 1Y -91.7%

Price Change 3Y -89.7%

Price Change 5Y -98.2%

1M CAGR (ann.) -44.1%

1Y CAGR (ann.) -91.8%

5Y CAGR (ann.) N/A

All-Time CAGR -66.7%

Valuation

PE Ratio -0.22

Forward PE N/A

PEG Ratio -0.00

Forward PEG 0.01

PS Ratio N/A

Forward PS 0.60

PB Ratio 0.95

P/FCF Ratio -0.38

P/Adj. FCF Ratio -0.33

P/OCF Ratio -0.31

EV/Sales N/A

EV/EBIT -0.18

EV/EBITDA -0.13

EV/FCF -0.15

Earnings Yield -449.5%

FCF Yield -261.4%

Adj. FCF Yield -305.7%

Financial Health

Net Cash $2.39M

Total Debt $0

Cash & Short-Term Investments $2.39M

Total Assets $5.59M

Current Ratio 3.73

Quick Ratio 3.73

Debt / Equity Ratio 0.00

Debt / EBITDA -0.00

Debt / FCF -0.00

OCF / Debt N/A

Interest Coverage 0.00

Altman Z-Score -13.64

Piotroski F-Score 2

Margins & Profitability

Gross Profit Margin 0.0%

Operating Profit Margin 0.0%

EBITDA Margin 0.0%

Net Profit Margin 0.0%

FCF Margin N/A

Adj. FCF Margin N/A

SBC / Revenue 0.0%

SBC Impact (per share) -17.0%

Returns

Return on Assets -206.6%

Return on Equity -406.4%

Return on Invested Capital -284.8%

Return on Capital Employed -284.8%

Return on Tangible Assets -206.6%

Historical Growth (CAGR)

Revenue CAGR 3Y N/A

Revenue CAGR 5Y N/A

Revenue CAGR 10Y N/A

EPS CAGR 3Y 10.4%

EPS CAGR 5Y N/A

EPS CAGR 10Y N/A

FCF CAGR 3Y -30.9%

FCF CAGR 5Y N/A

FCF CAGR 10Y N/A

Analyst Forecasts

Analyst Rating Buy

Analyst Count 1

EPS Growth Next 3Y 91.5%

Revenue Growth Next 3Y N/A

Earnings Date Nov 8, 2026

EPS Estimate (next Q) -$0.91

EPS Growth Est (next Q) -30.5%

Revenue Est (next Q) N/A

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $32

Price Target Upside 2835.8%

Cash Flow

Operating Cash Flow $-10.16M

Free Cash Flow $-10.16M

Adj. Free Cash Flow $-11.89M

FCF Per Share -$3.49

OCF Per Share -$3.49

OCF/S Ratio 0.0%

Income Statement

Revenue $0

Gross Profit $-956

Operating Income $-11.65M

EBITDA $-11.56M

Net Income $-8.22M

EPS (Diluted) -$4.90

Revenue / Employee N/A

Profit / Employee $-1.64M

Employees 5